Acelyrin Inc. (SLRN)
2.04
-0.06 (-2.86%)
At close: Jan 15, 2025, 12:59 PM
undefined% (undefined)
| Bid | 2.03 |
| Market Cap | 204.59M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.46 |
| PE Ratio (ttm) | -0.83 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 2.04 |
| Volume | 553,527 |
| Avg. Volume (20D) | 942,962 |
| Open | 2.16 |
| Previous Close | 2.10 |
| Day's Range | 2.02 - 2.16 |
| 52-Week Range | 1.91 - 8.88 |
| Beta | undefined |
About SLRN
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials...
Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2023
Employees 135
Stock Exchange NASDAQ
Ticker Symbol SLRN
Website https://www.acelyrin.com
Analyst Forecast
According to 5 analyst ratings, the average rating for SLRN stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 194.22% from the latest price.
Buy 40.00%
Hold 60.00%
Sell 0.00%
1 week ago ·
Source
-36.96%
Acelyrin shares are trading lower after HC Wainwri...
Unlock content with
Pro Subscription
1 week ago ·
Source
-8.64%
ACELYRIN shares are trading higher after the company announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease.
